KRSA
Korsana Biosciences Inc.
KRSA | NASDAQ
$31.25
+$1.11 (+3.68%)
Nov 2, 2026, 12:40 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | 2.07M | 2M | n/a | 297K | 3.32M | 2.3M |
Cost of Revenue | n/a | n/a | 1.32M | 5.58M | n/a | 56.41M |
Gross Profit | 2.07M | 2M | -1.32M | -5.28M | 3.32M | -54.12M |
Operating Income | -4.97M | -3.63M | -12.95M | -18.54M | -55.2M | -81.27M |
Interest Income | 128K | 208K | 358K | 294K | n/a | 588K |
Pretax Income | -3.53M | -3.06M | -12.59M | -18.25M | -51.65M | -77.8M |
Net Income | -3.53M | -3.06M | -5.26M | -44.08M | -51.65M | -77.8M |
Selling & General & Admin | 6.09M | 5.34M | 8.33M | 13.26M | 20.62M | 28.82M |
Research & Development | 959K | 286K | 1.52M | 5.98M | 37.64M | 56.41M |
Other Expenses | n/a | n/a | 1.79M | -5.98M | 259K | -58.08M |
Operating Expenses | 7.05M | 5.63M | 11.64M | 13.26M | 58.52M | 27.15M |
Interest Expense | n/a | n/a | n/a | n/a | 16K | n/a |
Selling & Marketing Expenses | n/a | n/a | 200K | 400K | n/a | n/a |
Cost & Expenses | 7.05M | 5.63M | 12.95M | 18.84M | 58.52M | 83.56M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 460.71K | 359.71K | 334K | 310.43K | 279.6K | 217.16K |
Shares Outstanding (Diluted) | 460.71K | 359.71K | 334K | 310.43K | 279.6K | 217.16K |
EPS (Basic) | -7.63 | -8.47 | -62.93 | -141.05 | -184.80 | -334.60 |
EPS (Diluted) | -7.63 | -8.47 | -62.93 | -141.05 | -184.80 | -334.60 |
EBITDA | -3.53M | -3.06M | -9.58M | -18.18M | -53.84M | -80.64M |
EBIT | -3.53M | -3.06M | -9.65M | -18.25M | -54.31M | -82.93M |
Depreciation & Amortization | n/a | n/a | 65K | 65K | 472K | 2.3M |
Add to Watchlist
Select watchlists to add or remove KRSA